Layton J Bradley, Kim Yoonsang, Alexander G Caleb, Emery Sherry L
Department of Epidemiology, University of North Carolina at Chapel Hill.
NORC at the University of Chicago, Chicago, Illinois.
JAMA. 2017 Mar 21;317(11):1159-1166. doi: 10.1001/jama.2016.21041.
Testosterone initiation increased substantially in the United States from 2000 to 2013, especially among men without clear indications. Direct-to-consumer advertising (DTCA) also increased during this time.
To investigate associations between televised DTCA and testosterone testing and initiation in the United States.
DESIGN, SETTING, AND POPULATION: Ecologic study conducted in designated market areas (DMAs) in the United States. Monthly testosterone advertising ratings were linked to DMA-level testosterone use data from 2009-2013 derived from commercial insurance claims. Associations between DTCA and testosterone testing, initiation, and initiation without recent baseline tests were estimated using Poisson generalized estimating equations.
Monthly Nielsen ratings for testosterone DTCA in the 75 largest DMAs.
(1) Rates of new serum testosterone testing; (2) rates of testosterone initiation (in-office injection, surgical implant, or pharmacy dispensing) for all testosterone products combined and for specific brands; and (3) rates of testosterone initiation without recent serum testosterone testing.
Of 17 228 599 commercially insured men in the 75 DMAs, 1 007 990 (mean age, 49.6 [SD, 11.5] years) had new serum testosterone tests and 283 317 (mean age, 51.8 [SD, 11.3] years) initiated testosterone treatment. Advertising intensity varied by geographic region and time, with the highest intensity seen in the southeastern United States and with months ranging from no ad exposures to a mean of 13.6 exposures per household. Nonbranded advertisements were common prior to 2012, with branded advertisements becoming more common during and after 2012. Each household advertisement exposure was associated with a monthly increase in rates of new testosterone testing (rate ratio [RR], 1.006; 95% CI, 1.004-1.008), initiation (RR, 1.007; 95% CI, 1.004-1.010), and initiation without a recent test (RR, 1.008; 95% CI, 1.002-1.013). Mean absolute rate increases were 0.14 tests (95% CI, 0.09-0.19), 0.05 new initiations (95% CI, 0.03-0.08), and 0.02 initiations without a recent test (95% CI, 0.01-0.03) per 10 000 men for each monthly ad exposure over the entire period.
Among US men residing in the 75 designated market areas, regional exposure to televised direct-to-consumer advertising was associated with greater testosterone testing, new initiation, and initiation without recent testing.
2000年至2013年期间,美国睾酮起始治疗显著增加,尤其是在没有明确指征的男性中。在此期间,直接面向消费者的广告(DTCA)也有所增加。
调查美国电视DTCA与睾酮检测及起始治疗之间的关联。
设计、设置和人群:在美国指定市场区域(DMA)进行的生态学研究。2009年至2013年每月的睾酮广告评级与来自商业保险理赔的DMA水平的睾酮使用数据相关联。使用泊松广义估计方程估计DTCA与睾酮检测、起始治疗以及无近期基线检测的起始治疗之间的关联。
75个最大DMA中睾酮DTCA的每月尼尔森评级。
(1)新的血清睾酮检测率;(2)所有睾酮产品联合及特定品牌的睾酮起始治疗率(门诊注射、手术植入或药房配药);(3)无近期血清睾酮检测的睾酮起始治疗率。
在75个DMA的17228599名商业保险男性中,1007990人(平均年龄49.6[标准差,11.5]岁)进行了新的血清睾酮检测,283317人(平均年龄51.8[标准差,11.3]岁)开始了睾酮治疗。广告强度因地理区域和时间而异,在美国东南部强度最高,每月每户广告曝光次数从无曝光到平均13.6次不等。2012年之前非品牌广告很常见,2012年期间及之后品牌广告变得更常见。每户广告曝光与每月新的睾酮检测率增加相关(率比[RR],1.006;95%置信区间,1.004 - 1.008)、起始治疗率增加(RR,1.007;95%置信区间,1.004 - 1.010)以及无近期检测的起始治疗率增加(RR,1.008;95%置信区间,1.002 - 1.013)。在整个期间,每10000名男性中,每次每月广告曝光的平均绝对率增加分别为0.14次检测(95%置信区间,0.09 - 0.19)、0.05次新的起始治疗(95%置信区间,0.03 - 0.08)和0.02次无近期检测的起始治疗(95%置信区间,0.01 - 0.03)。
在美国居住在75个指定市场区域的男性中,区域电视直接面向消费者广告曝光与更多的睾酮检测、新的起始治疗以及无近期检测的起始治疗相关。